**Table 1.** Types, mechanisms, and functions of post-translational modifications of proteins

|  |  |  |
| --- | --- | --- |
| PTM | Machine made | Feature |
| phosphorylation | ATP phosphate groups are transferred to specific sites on proteins by phosphorylated kinases | Regulates nearly all aspects of cellular processes, from cell signaling, signal transduction, cell cycle, resilience to growth and development (Singh et al., 2017) |
| glycosylation | By covalent attachment of glycans to amino acid functional groups | Involved cell signal transduction, the screening of biomarkers, which affects the spatial conformation, activity and localization of proteins (Schjoldager, Narimatsu, Joshi, & Clausen, 2020) |
| ubiquitination | Protein abundance is controlled by ubiquitinating and deubiquitinating enzymes mediating protein degradation and stability | Virtually every process in the cell is regulated by the ubiquitin system, from the cell cycle to cell migration, invasion, apoptosis, differentiation, and so on (Samaržija, 2021) |
| acetylation | It is mainly the process of acid anhydride or acid reaction with alcohol to produce ester | It is an important epigenetic marker that regulates cells' response to inflammation and maintains cellular status (Shvedunova & Akhtar, 2022) |
| methylation | Methyltransferase catalyzes the production of S-adenosylmethionine | It is involved in chromosome assembly, protein and nucleic acid transport and metabolism, intracellular signaling, etc (Jakobsson, 2021) |
| succinylation | The process of transferring succinyl-CoA to proteins by succinylase | It is involved in metabolic regulation and affects the function of mitochondrial proteins and metabolic pathways (Yang & Gibson, 2019) |
| lipidation | Proteins are covalently attached to hydrophobic lipid molecules after ribosome synthesis | The lipid chain has a good compatibility with the biolipid membrane, and the protein is fixed on the cell membrane (Y. Zhang, Qin, Sun, Chu, & Zhou, 2021) |
| lactylation | Lysine residues on histones were modified with lactic acid as substrate | Participate in glycolysis, regulate cell cycle and cell proliferation, macrophage polarization, blood vessel function, mitochondria, nervous system regulation and other important life activities (A. N. Chen et al., 2021) |

**Table 2**. Summary of studies on the effects of protein phosphorylation on diagnosis, treatment, and prognosis of prostate cancer

|  |  |  |  |
| --- | --- | --- | --- |
| protein | Phosphorylation site | significance | reference |
| ABI2 | Ser-183 | PIM1-phosphorylated ABI2 promotes tumor invasion, and PIM inhibitor therapy significantly reduces intramuscular PCa invasion | (Jensen et al., 2023) |
| AKT | Thr-305, Thr-309, Ser-472, Ser-473, Ser-474, Thr-308, Tyr-474 | Uncovering the occurrence and development mechanisms of PCa, providing potential targets and possible drugs for the treatment of prostate cancer, and providing solutions to PCa cross-resistance | (Chang et al., 2021; C. P. Liao et al., 2018; L. Liu et al., 2023; M. Liu et al., 2023; Turkekul, Colpan, Baykul, Ozdemir, & Erdogan, 2018) |
| AR | Ser81, Ser213, Tyr534 | Providing potential targets and possible drugs for the treatment of PCa | (X. Gao et al., 2021; Kuo et al., 2019; H. P. Lin et al., 2019) |
| YAP1 | Thr-119, Thr-154, Thr-412, Ser-138, Ser-367, Ser-400, Ser-403 | To reveal the occurrence and development mechanism of PCa | (Russo et al., 2018; Z. Wu et al., 2023) |
| STAT3 | Tyr-705, Ser-727 | To elucidate the occurrence and development mechanisms of PCa, and to provide targets and possible drugs for the treatment of metastatic PCa | (Babaei, Khadem Ansari, Aziz, & Bazl, 2020; Henderson et al., 2019; Kwan et al., 2019; W. Lin et al., 2018) |
| p38 | Thr-72, Ser-74, Ser-77 | To elucidate the occurrence and developmental mechanisms of PCa and provide targets for PCa treatment | (Waseem, Khan, Haq, & Syed, 2022; Yuan et al., 2019) |
| ERK 1/2 | Thr-185, Thr-190, Thr-202, Tyr-187, Tyr-204, Ser-246, Ser-248 | Elucidation of the pathogenesis of PCa | (Borel et al., 2020; Zheng et al., 2020) |
| EGFR | Ser-695, Thr-693, Thr-678, | To reveal the occurrence and development mechanism of PCa and provide drugs for the treatment of PCa | (J. Li et al., 2022; P. Zhang et al., 2023; Zhi et al., 2018) |
| GSK3β | Ser-9, Tyr-216 | It is used to prevent or treat PCa metastases and is used to elucidate the occurrence and development mechanisms of PCa | (Barboro et al., 2020; Fang et al., 2020; S. Wu et al., 2018; S. Wu et al., 2021) |
| FOXO1 | Thr-24, Ser-249, Ser-256, Ser-319, Ser-322, Ser-325, Ser-329 | To elucidate the occurrence and development mechanisms of PCa and to provide a target for the treatment of PCa | (Cheng et al., 2023; Gheghiani, Shang, & Fu, 2020; Yan & Huang, 2019) |
| NANOG | Ser68 | Help identify new drug targets and improve treatment strategies for PCa | (Wang et al., 2019) |
| p65 | Ser-311, Ser-276, Ser-75 | To elucidate the occurrence and development mechanisms of prostate cancer and to provide a target for the treatment of PCa | (Bonacini et al., 2019; Q. Li et al., 2021) |
| SPOP | Ser-59, Ser-171, Ser-226 | WT-SPOP prevents the development of PCa | (Nikhil, Haymour, Kamra, & Shah, 2021) |
| p53 | Thr-18, Thr-55, Ser-20, Ser-46, Ser-315, Ser-392, Lys-372 | Switching off DDX49 is a promising new therapy for PCa patients | (Tao et al., 2023) |
| SHP1 | Tyr 536 | Dioscin can help treat androgen-sensitive PCa | (He et al., 2020) |
| Smad2 | Thr-220, Ser-245, Ser-250, Ser-255, Ser-240, Ser-465, Ser-467 | NR4A3 maintains MT-2 signaling to inhibit PCa cell invasion, tumor growth and metastasis | (H. Y. Lin et al., 2022) |
| c-Jun | / | JNK signal axis as a possible therapeutic target for PCa patients | (Schröder, Asimakopoulou, Tillmann, Koschmieder, & Weiskirchen, 2020) |
| EphA2 | Tyr-588, Tyr-594, Tyr-735, Tyr-930, Ser-897 | RES may have anti-Vasculogenic mimicry (VM) effects by inhibiting EphA3/twist-VE-cadherin/AKT signaling cascade in PCa PC-2 cells | (Han, Lee, & Lee, 2022) |
| Twist1 | Ser-68 | To better understand the occurrence and development mechanism of PCa | (Fan et al., 2019) |
| P-eIF2α | / | To better understand the occurrence and development mechanism of PCa | (Nguyen et al., 2018) |
| UHRF1 | Ser-298, Ser-639 | For the first time, a new molecular mechanism of abiraterone resistance via the PI3K/AKT-UHRF1 signaling pathway has been discovered | (Fu et al., 2023) |
| EphA3 | / | Providing a new biomarker for PCa | (Cai et al., 2022) |
| Plk1 | Thr-210, Ser-137 | To better understand the occurrence and development mechanisms of prostate cancer and to provide anti-prostate cancer medicines | (Z. Zhang et al., 2021) |
| ErbB2 | Tyr-1248 | MTE plays a potential antitumor role in PCa by inhibiting the ErbB2-GSK3β-HIF1α signaling axis | (X. Chen et al., 2022) |

**Table 3.** Summary of studies on the effects of protein ubiquitination on diagnosis, treatment and prognosis of prostate cancer

|  |  |  |  |
| --- | --- | --- | --- |
| protein | ubiquitination site | significance | reference |
| Caprin1 | / | To reveal the development mechanism of PCa | (Shi et al., 2019) |
| Cyclin E1 | Thr-77, Thr-395 | To reveal the development mechanism of PCa | (Ju et al., 2019) |
| EGFR | Lys-48, Lys-63 | To reveal the development mechanism of PCa | (Zhou et al., 2022) |
| STAT4 | Lys-350 | Providing a target for targeted PCa therapy | (Xiao et al., 2023) |
| HK2 | Lys-315, Lys-492 | A possible strategy to prevent chemotherapy resistance in prostate cancer is proposed | (Shangguan et al., 2021) |
| HDAC1 | Lys-444, Lys-476 | Uncover the mechanism of prostate cancer and create a new basis for targeted therapy | (Hao et al., 2022) |
| c-Myc | Thr-7，Ser-77 | Providing a target for targeted PCa therapy | (Ding et al., 2021; Ge et al., 2021) |
| SIX1 | / | Development of a novel and effective strategy to treat CRPC | (Y. Liao et al., 2022) |
| PTEN | Lys-13，Lys-289 | Elucidation of the origin and development mechanism of prostate cancer | (Deng et al., 2021) |
| CDKN1A | Ser-2 | Providing new prognostic and therapeutic targets for PCa | (Lai et al., 2021) |
| S100A9 | / | Providing a target for targeted PCa therapy | (Y. Zhang et al., 2022) |
| AR/AR-V7 | Lys-48 | Uncover the mechanism of prostate cancer and create a new basis for clinical diagnosis and targeted therapy | (L. Gao et al., 2021; Liu et al., 2021; S. Lv et al., 2021) |
| RAB1A | / | SGOL2 promotes prostate cancer progression by inhibiting ubiquitination of RAB1A | (T. Lv et al., 2022) |
| Smad4 | Lys-519 | It offers a potential therapeutic strategy for advanced PCa treatment | (Gao et al., 2022) |

# References

Babaei, G., Khadem Ansari, M. H., Aziz, S. G., & Bazl, M. R. (2020). Alantolactone inhibits stem-like cell phenotype, chemoresistance and metastasis in PC3 cells through STAT3 signaling pathway. *Res Pharm Sci, 15*(6), 551-562. doi:10.4103/1735-5362.301340

Barboro, P., Benelli, R., Tosetti, F., Costa, D., Capaia, M., Astigiano, S., . . . Ferrari, N. (2020). Aspartate β-hydroxylase targeting in castration-resistant prostate cancer modulates the NOTCH/HIF1α/GSK3β crosstalk. *Carcinogenesis, 41*(9), 1246-1252. doi:10.1093/carcin/bgaa053

Bonacini, M., Negri, A., Davalli, P., Naponelli, V., Ramazzina, I., Lenzi, C., . . . Rizzi, F. (2019). Clusterin Silencing in Prostate Cancer Induces Matrix Metalloproteinases by an NF-κB-Dependent Mechanism. *J Oncol, 2019*, 4081624. doi:10.1155/2019/4081624

Borel, M., Lollo, G., Magne, D., Buchet, R., Brizuela, L., & Mebarek, S. (2020). Prostate cancer-derived exosomes promote osteoblast differentiation and activity through phospholipase D2. *Biochim Biophys Acta Mol Basis Dis, 1866*(12), 165919. doi:10.1016/j.bbadis.2020.165919

Cai, C., Zhang, M., Liu, L., Zhang, H., Guo, Y., Lan, T., . . . Li, S. (2022). ADAM10-cleaved ephrin-A5 contributes to prostate cancer metastasis. *Cell Death Dis, 13*(5), 453. doi:10.1038/s41419-022-04893-8

Chang, M., Zhu, D., Chen, Y., Zhang, W., Liu, X., Li, X. L., . . . Guo, H. (2021). Total Flavonoids of Litchi Seed Attenuate Prostate Cancer Progression Via Inhibiting AKT/mTOR and NF-kB Signaling Pathways. *Front Pharmacol, 12*, 758219. doi:10.3389/fphar.2021.758219

Chen, A. N., Luo, Y., Yang, Y. H., Fu, J. T., Geng, X. M., Shi, J. P., & Yang, J. (2021). Lactylation, a Novel Metabolic Reprogramming Code: Current Status and Prospects. *Front Immunol, 12*, 688910. doi:10.3389/fimmu.2021.688910

Chen, X., Luo, Z., Liu, X., Li, X., Li, Q., Zhang, W., . . . Guo, H. (2022). Marsdenia tenacissima (Roxb.) Moon injection exerts a potential anti-tumor effect in prostate cancer through inhibiting ErbB2-GSK3β-HIF1α signaling axis. *J Ethnopharmacol, 295*, 115381. doi:10.1016/j.jep.2022.115381

Cheng, L., He, Q., Liu, B., Chen, L., Lv, F., Li, X., . . . Xing, Y. (2023). SGK2 promotes prostate cancer metastasis by inhibiting ferroptosis via upregulating GPX4. *Cell Death Dis, 14*(1), 74. doi:10.1038/s41419-023-05614-5

Deng, R., Guo, Y., Li, L., He, J., Qiang, Z., Zhang, H., . . . Yu, J. (2021). BAP1 suppresses prostate cancer progression by deubiquitinating and stabilizing PTEN. *Mol Oncol, 15*(1), 279-298. doi:10.1002/1878-0261.12844

Ding, T., Zhu, Y., Jin, H., Zhang, P., Guo, J., & Zheng, J. (2021). Circular RNA circ\_0057558 Controls Prostate Cancer Cell Proliferation Through Regulating miR-206/USP33/c-Myc Axis. *Front Cell Dev Biol, 9*, 644397. doi:10.3389/fcell.2021.644397

Fan, J., Fan, Y., Wang, X., Niu, L., Duan, L., Yang, J., . . . Luo, C. (2019). PLCε regulates prostate cancer mitochondrial oxidative metabolism and migration via upregulation of Twist1. *J Exp Clin Cancer Res, 38*(1), 337. doi:10.1186/s13046-019-1323-8

Fang, F., Li, Q., Wu, M., Nie, C., Xu, H., & Wang, L. (2020). CD147 promotes epithelial-mesenchymal transition of prostate cancer cells via the Wnt/β-catenin pathway. *Exp Ther Med, 20*(4), 3154-3160. doi:10.3892/etm.2020.9058

Fu, Y., Cao, T., Zou, X., Ye, Y., Liu, Y., Peng, Y., . . . Li, X. (2023). AKT1 regulates UHRF1 protein stability and promotes the resistance to abiraterone in prostate cancer. *Oncogenesis, 12*(1), 1. doi:10.1038/s41389-022-00446-y

Gao, L., Zhang, W., Zhang, J., Liu, J., Sun, F., Liu, H., . . . Han, B. (2021). KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer. *Cancer Res, 81*(4), 1026-1039. doi:10.1158/0008-5472.Can-20-1965

Gao, P., Hao, J. L., Xie, Q. W., Han, G. Q., Xu, B. B., Hu, H., . . . Dong, X. M. (2022). PELO facilitates PLK1-induced the ubiquitination and degradation of Smad4 and promotes the progression of prostate cancer. *Oncogene, 41*(21), 2945-2957. doi:10.1038/s41388-022-02316-8

Gao, X., Liang, J., Wang, L., Zhang, Z., Yuan, P., Wang, J., . . . Liu, X. (2021). Phosphorylation of the androgen receptor at Ser81 is co-sustained by CDK1 and CDK9 and leads to AR-mediated transactivation in prostate cancer. *Mol Oncol, 15*(7), 1901-1920. doi:10.1002/1878-0261.12968

Ge, J., Yu, W., Li, J., Ma, H., Wang, P., Zhou, Y., . . . Shi, G. (2021). USP16 regulates castration-resistant prostate cancer cell proliferation by deubiquitinating and stablizing c-Myc. *J Exp Clin Cancer Res, 40*(1), 59. doi:10.1186/s13046-021-01843-8

Gheghiani, L., Shang, S., & Fu, Z. (2020). Targeting the PLK1-FOXO1 pathway as a novel therapeutic approach for treating advanced prostate cancer. *Sci Rep, 10*(1), 12327. doi:10.1038/s41598-020-69338-8

Han, D. S., Lee, H. J., & Lee, E. O. (2022). Resveratrol suppresses serum-induced vasculogenic mimicry through impairing the EphA2/twist-VE-cadherin/AKT pathway in human prostate cancer PC-3 cells. *Sci Rep, 12*(1), 20125. doi:10.1038/s41598-022-24414-z

Hao, L., Dong, Y., Zhang, J. J., He, H. G., Chen, J. G., Zhang, S. Q., . . . Shi, Z. D. (2022). Melatonin decreases androgen-sensitive prostate cancer growth by suppressing SENP1 expression. *Transl Androl Urol, 11*(1), 91-103. doi:10.21037/tau-21-1110

He, S., Yang, J., Hong, S., Huang, H., Zhu, Q., Ye, L., . . . Gao, Y. (2020). Dioscin Promotes Prostate Cancer Cell Apoptosis and Inhibits Cell Invasion by Increasing SHP1 Phosphorylation and Suppressing the Subsequent MAPK Signaling Pathway. *Front Pharmacol, 11*, 1099. doi:10.3389/fphar.2020.01099

Henderson, V. M., Hawsawi, O., Burton, L. J., Campbell, T., Trice, K., Dougan, J., . . . Odero-Marah, V. A. (2019). Cancer-bone microenvironmental interactions promotes STAT3 signaling. *Mol Carcinog, 58*(8), 1349-1361. doi:10.1002/mc.23019

Jakobsson, M. E. (2021). Enzymology and significance of protein histidine methylation. *J Biol Chem, 297*(4), 101130. doi:10.1016/j.jbc.2021.101130

Jensen, C. C., Clements, A. N., Liou, H., Ball, L. E., Bethard, J. R., Langlais, P. R., . . . Warfel, N. A. (2023). PIM1 phosphorylates ABI2 to enhance actin dynamics and promote tumor invasion. *J Cell Biol, 222*(6). doi:10.1083/jcb.202208136

Ju, L. G., Zhu, Y., Long, Q. Y., Li, X. J., Lin, X., Tang, S. B., . . . Wu, M. (2019). SPOP suppresses prostate cancer through regulation of CYCLIN E1 stability. *Cell Death Differ, 26*(6), 1156-1168. doi:10.1038/s41418-018-0198-0

Kuo, Y. Y., Huo, C., Lin, C. Y., Lin, H. P., Liu, J. S., Wang, W. C., . . . Chuu, C. P. (2019). Caffeic acid phenethyl ester suppresses androgen receptor signaling and stability via inhibition of phosphorylation on Ser81 and Ser213. *Cell Commun Signal, 17*(1), 100. doi:10.1186/s12964-019-0404-9

Kwan, H. Y., Liu, B., Huang, C., Fatima, S., Su, T., Zhao, X., . . . Bian, Z. (2019). Signal transducer and activator of transcription-3 drives the high-fat diet-associated prostate cancer growth. *Cell Death Dis, 10*(9), 637. doi:10.1038/s41419-019-1842-4

Lai, W., Zhu, W., Xiao, C., Li, X., Wang, Y., Han, Y., . . . Wen, X. (2021). HJURP promotes proliferation in prostate cancer cells through increasing CDKN1A degradation via the GSK3β/JNK signaling pathway. *Cell Death Dis, 12*(6), 583. doi:10.1038/s41419-021-03870-x

Li, J., Wu, H., Lv, S., Quan, D., Yang, D., Xu, J., . . . Wei, Q. (2022). Enhanced antitumor efficacy by combining afatinib with MDV3100 in castration-resistant prostate cancer. *Pharmazie, 77*(2), 59-66. doi:10.1691/ph.2022.1948

Li, Q., Xia, D., Wang, Z., Liu, B., Zhang, J., Peng, P., . . . Chen, X. (2021). Circadian Rhythm Gene PER3 Negatively Regulates Stemness of Prostate Cancer Stem Cells via WNT/β-Catenin Signaling in Tumor Microenvironment. *Front Cell Dev Biol, 9*, 656981. doi:10.3389/fcell.2021.656981

Liao, C. P., Lin, T. P., Li, P. C., Geary, L. A., Chen, K., Vaikari, V. P., . . . Shih, J. C. (2018). Loss of MAOA in epithelia inhibits adenocarcinoma development, cell proliferation and cancer stem cells in prostate. *Oncogene, 37*(38), 5175-5190. doi:10.1038/s41388-018-0325-x

Liao, Y., Sun, W., Shao, Z., Liu, Y., Zhong, X., Deng, Y., . . . Liu, J. (2022). A SIX1 degradation inducer blocks excessive proliferation of prostate cancer. *Int J Biol Sci, 18*(6), 2439-2451. doi:10.7150/ijbs.67873

Lin, H. P., Ho, H. M., Chang, C. W., Yeh, S. D., Su, Y. W., Tan, T. H., & Lin, W. J. (2019). DUSP22 suppresses prostate cancer proliferation by targeting the EGFR-AR axis. *Faseb j, 33*(12), 14653-14667. doi:10.1096/fj.201802558RR

Lin, H. Y., Ko, C. J., Lo, T. Y., Wu, S. R., Lan, S. W., Huang, C. A., . . . Lee, M. S. (2022). Matriptase-2/NR4A3 axis switches TGF-β action toward suppression of prostate cancer cell invasion, tumor growth, and metastasis. *Oncogene, 41*(20), 2833-2845. doi:10.1038/s41388-022-02303-z

Lin, W., Luo, J., Sun, Y., Lin, C., Li, G., Niu, Y., & Chang, C. (2018). ASC-J9(®) suppresses prostate cancer cell invasion via altering the sumoylation-phosphorylation of STAT3. *Cancer Lett, 425*, 21-30. doi:10.1016/j.canlet.2018.02.007

Liu, L., Li, M., Zhang, J., Xu, D., Guo, Y., Zhang, H., & Cang, S. (2023). KIF14 mediates cabazitaxel-docetaxel cross-resistance in advanced prostate cancer by promoting AKT phosphorylation. *Arch Biochem Biophys, 737*, 109551. doi:10.1016/j.abb.2023.109551

Liu, M., Zhang, Y., Zhang, A., Deng, Y., Gao, X., Wang, J., . . . Liu, X. (2023). Compound K is a potential clinical anticancer agent in prostate cancer by arresting cell cycle. *Phytomedicine, 109*, 154584. doi:10.1016/j.phymed.2022.154584

Liu, Y., Yu, C., Shao, Z., Xia, X., Hu, T., Kong, W., . . . Huang, H. (2021). Selective degradation of AR-V7 to overcome castration resistance of prostate cancer. *Cell Death Dis, 12*(10), 857. doi:10.1038/s41419-021-04162-0

Lv, S., Song, Q., Chen, G., Cheng, E., Chen, W., Cole, R., . . . Wang, Z. (2021). Regulation and targeting of androgen receptor nuclear localization in castration-resistant prostate cancer. *J Clin Invest, 131*(4). doi:10.1172/jci141335

Lv, T., He, D., Zhang, X., Guo, X., Li, Z., Zhang, A., . . . Wang, Z. (2022). SGOL2 promotes prostate cancer progression by inhibiting RAB1A ubiquitination. *Aging (Albany NY), 14*(24), 10050-10066. doi:10.18632/aging.204443

Nguyen, H. G., Conn, C. S., Kye, Y., Xue, L., Forester, C. M., Cowan, J. E., . . . Ruggero, D. (2018). Development of a stress response therapy targeting aggressive prostate cancer. *Sci Transl Med, 10*(439). doi:10.1126/scitranslmed.aar2036

Nikhil, K., Haymour, H. S., Kamra, M., & Shah, K. (2021). Phosphorylation-dependent regulation of SPOP by LIMK2 promotes castration-resistant prostate cancer. *Br J Cancer, 124*(5), 995-1008. doi:10.1038/s41416-020-01197-6

Russo, J. W., Liu, X., Ye, H., Calagua, C., Chen, S., Voznesensky, O., . . . Chen, S. (2018). Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer. *Cancer Lett, 438*, 97-104. doi:10.1016/j.canlet.2018.09.014

Samaržija, I. (2021). Post-Translational Modifications That Drive Prostate Cancer Progression. *Biomolecules, 11*(2). doi:10.3390/biom11020247

Schjoldager, K. T., Narimatsu, Y., Joshi, H. J., & Clausen, H. (2020). Global view of human protein glycosylation pathways and functions. *Nat Rev Mol Cell Biol, 21*(12), 729-749. doi:10.1038/s41580-020-00294-x

Schröder, S. K., Asimakopoulou, A., Tillmann, S., Koschmieder, S., & Weiskirchen, R. (2020). TNF-α controls Lipocalin-2 expression in PC-3 prostate cancer cells. *Cytokine, 135*, 155214. doi:10.1016/j.cyto.2020.155214

Shangguan, X., He, J., Ma, Z., Zhang, W., Ji, Y., Shen, K., . . . Xue, W. (2021). SUMOylation controls the binding of hexokinase 2 to mitochondria and protects against prostate cancer tumorigenesis. *Nat Commun, 12*(1), 1812. doi:10.1038/s41467-021-22163-7

Shi, Q., Zhu, Y., Ma, J., Chang, K., Ding, D., Bai, Y., . . . Wang, C. (2019). Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly. *Mol Cancer, 18*(1), 170. doi:10.1186/s12943-019-1096-x

Shvedunova, M., & Akhtar, A. (2022). Modulation of cellular processes by histone and non-histone protein acetylation. *Nat Rev Mol Cell Biol, 23*(5), 329-349. doi:10.1038/s41580-021-00441-y

Singh, V., Ram, M., Kumar, R., Prasad, R., Roy, B. K., & Singh, K. K. (2017). Phosphorylation: Implications in Cancer. *Protein J, 36*(1), 1-6. doi:10.1007/s10930-017-9696-z

Tao, J., Ge, Q., Meng, J., Liang, C., Hao, Z., & Zhou, J. (2023). Overexpression of DDX49 in prostate cancer is associated with poor prognosis. *BMC Urol, 23*(1), 66. doi:10.1186/s12894-023-01251-4

Turkekul, K., Colpan, R. D., Baykul, T., Ozdemir, M. D., & Erdogan, S. (2018). Esculetin Inhibits the Survival of Human Prostate Cancer Cells by Inducing Apoptosis and Arresting the Cell Cycle. *J Cancer Prev, 23*(1), 10-17. doi:10.15430/jcp.2018.23.1.10

Wang, X., Jin, J., Wan, F., Zhao, L., Chu, H., Chen, C., . . . Wang, P. (2019). AMPK Promotes SPOP-Mediated NANOG Degradation to Regulate Prostate Cancer Cell Stemness. *Dev Cell, 48*(3), 345-360.e347. doi:10.1016/j.devcel.2018.11.033

Waseem, D., Khan, G. M., Haq, I. U., & Syed, D. N. (2022). Dibutylstannanediyl (2Z,2'Z)-bis(4-(benzylamino)-4-oxobut-2-enoate inhibits prostate cancer progression by activating p38 MAPK/PPARα/SMAD4 signaling. *Toxicol Appl Pharmacol, 449*, 116127. doi:10.1016/j.taap.2022.116127

Wu, S., Huang, J., Hui, K., Yue, Y., Gu, Y., Ning, Z., . . . Wu, K. (2018). 2'‑Hydroxyflavanone inhibits epithelial‑mesenchymal transition, and cell migration and invasion via suppression of the Wnt/β‑catenin signaling pathway in prostate cancer. *Oncol Rep, 40*(5), 2836-2843. doi:10.3892/or.2018.6678

Wu, S., Yue, Y., Gu, Y., Wang, Q., Liu, T., Li, L., . . . Wu, K. (2021). MUC15 loss facilitates epithelial-mesenchymal transition and cancer stemness for prostate cancer metastasis through GSK3β/β-catenin signaling. *Cell Signal, 84*, 110015. doi:10.1016/j.cellsig.2021.110015

Wu, Z., Ge, L., Ma, L., Lu, M., Song, Y., Deng, S., . . . Zhang, S. (2023). TPM2 attenuates progression of prostate cancer by blocking PDLIM7-mediated nuclear translocation of YAP1. *Cell Biosci, 13*(1), 39. doi:10.1186/s13578-023-00993-w

Xiao, J., Sun, F., Wang, Y. N., Liu, B., Zhou, P., Wang, F. X., . . . Wang, Z. H. (2023). UBC9 deficiency enhances immunostimulatory macrophage activation and subsequent antitumor T cell response in prostate cancer. *J Clin Invest, 133*(4). doi:10.1172/jci158352

Yan, Y., & Huang, H. (2019). Interplay Among PI3K/AKT, PTEN/FOXO and AR Signaling in Prostate Cancer. *Adv Exp Med Biol, 1210*, 319-331. doi:10.1007/978-3-030-32656-2\_14

Yang, Y., & Gibson, G. E. (2019). Succinylation Links Metabolism to Protein Functions. *Neurochem Res, 44*(10), 2346-2359. doi:10.1007/s11064-019-02780-x

Yuan, L., Huang, X., Zhou, K., Zhu, X., Huang, B., Qiu, S., . . . Xu, L. (2019). Sea cucumber extract TBL-12 inhibits the proliferation, migration, and invasion of human prostate cancer cells through the p38 mitogen-activated protein kinase and intrinsic caspase apoptosis pathway. *Prostate, 79*(8), 826-839. doi:10.1002/pros.23788

Zhang, P., Chen, L., Zhou, F., He, Z., Wang, G., & Luo, Y. (2023). NRP1 promotes prostate cancer progression via modulating EGFR-dependent AKT pathway activation. *Cell Death Dis, 14*(2), 159. doi:10.1038/s41419-023-05696-1

Zhang, Y., Liu, F., Feng, Y., Xu, X., Wang, Y., Zhu, S., . . . Feng, N. (2022). CircRNA circ\_0006156 inhibits the metastasis of prostate cancer by blocking the ubiquitination of S100A9. *Cancer Gene Ther, 29*(11), 1731-1741. doi:10.1038/s41417-022-00492-z

Zhang, Y., Qin, Z., Sun, W., Chu, F., & Zhou, F. (2021). Function of Protein S-Palmitoylation in Immunity and Immune-Related Diseases. *Front Immunol, 12*, 661202. doi:10.3389/fimmu.2021.661202

Zhang, Z., Cheng, L., Zhang, Q., Kong, Y., He, D., Li, K., . . . Liu, X. (2021). Co-Targeting Plk1 and DNMT3a in Advanced Prostate Cancer. *Adv Sci (Weinh), 8*(13), e2101458. doi:10.1002/advs.202101458

Zheng, Y., Li, J. X., Chen, C. J., Lin, Z. Y., Liu, J. X., & Lin, F. J. (2020). Extracellular vesicle-derived circ\_SLC19A1 promotes prostate cancer cell growth and invasion through the miR-497/septin 2 pathway. *Cell Biol Int, 44*(4), 1037-1045. doi:10.1002/cbin.11303

Zhi, Y., Wu, X., Shen, W., Wang, Y., Zhou, X., He, P., . . . Zhou, Z. (2018). Synthesis and pharmacological evaluation of novel epidermal growth factor receptor inhibitors against prostate tumor cells. *Oncol Lett, 16*(5), 6522-6530. doi:10.3892/ol.2018.9438

Zhou, T., Chen, T., Lai, B., Zhang, W., Luo, X., Xia, D., . . . Xu, J. (2022). FBXW2 inhibits prostate cancer proliferation and metastasis via promoting EGFR ubiquitylation and degradation. *Cell Mol Life Sci, 79*(5), 268. doi:10.1007/s00018-022-04320-3